NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status
Policy / Regulatory

NMPA Releases 84th Batch of Reference Drugs for GQCE and First Batch Stripped of Status

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment
CompanyMedical Device

J&J MedTech Completes Pilot Enrollment for OMNY-AF Study on Atrial Fibrillation Treatment

Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015
CompanyDrug

Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015

Teva Pharmaceutical Reports Positive Phase III Results for TEV-'749 in Schizophrenia Trial
CompanyDrug

Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial

Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing
CompanyDeals

Neurodawn Pharmaceutical Secures Hundreds of Millions in Series C Financing

Suzhou Basecare Medical's BKA210 Receives Marketing Approval in Jiangsu Province
CompanyMedical Device

Suzhou Basecare Medical’s BKA210 Receives Marketing Approval in Jiangsu Province

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital
CompanyDeals

Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital

Novo Nordisk's Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH
CompanyDrug

Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH

Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes
CompanyDrug

Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study
CompanyDrug

Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures
CompanyDeals

Innovent Biologics Halts Subscription Agreement with Lostrancos Ventures

China's CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation
Policy / Regulatory

China’s CDE Releases 88th Batch of Reference Preparations for Generic Drug Evaluation